The acquisition will give Gilead access to an anti-cancer antibody drug conjugate in clinical development for treating breast and bladder cancers.
Gilead announced on Sept. 13, 2020 that it will acquire Immunomedics, a biopharmaceutical company focused on antibody-drug conjugate (ADC) technology, for approximately $21 billion.
Through the agreement, Gilead will acquire all outstanding shares of Immunomedics’ common stock for $88 per share, a Gilead press release said. After the tender offer is completed, Gilead will obtain all remaining shares not tendered in the offer through a second step merger at the same price as the tender offer.
The acquisition will give Gilead access to Trodelvy (sacituzumab govitecan-hziy), a Trop-2 directed ADC for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease, according to the press release. Currently, Trodelvy is involved in an ongoing Phase III trial for third line HR+/HER2- breast cancer and a registrational Phase II study for bladder cancer.
“This acquisition represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio. Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments,” said Daniel O’Day, chairman and CEO, Gilead, in the press release. “We look forward to welcoming the talented Immunomedics team to Gilead so we can continue to advance this important new medicine for the benefit of patients with cancer worldwide.”
“We are very pleased that Gilead recognized the value of Trodelvy—both for the important role it has already begun to play for patients with metastatic triple-negative breast cancer and for its potential to help many other patients with cancer in the future,” added Behzad Aghazadeh, PhD, executive chairman of Immunomedics, in the press release. “We are excited for the opportunities ahead of us as we join with Gilead to advance our shared mission in defeating cancer. By working with Gilead, we have the opportunity to accelerate our progress and improve care for patients in need of new therapies.”
In the United States, Trodelvy was approved by FDA in 2020 for treating metastatic triple-negative breast cancer in adult patients who have received at least two prior therapies for metastatic disease.
Source: Gilead, FDA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.